Wave Life Sciences shares plunged 58% on Thursday after a higher dose of its experimental obesity drug failed to show a clear improvement at reducing a dangerous type of belly fat.
On March 26, 2026, traders mulled Wave's weak high-dose obesity results against the company's large market opportunity.
Wave Life Sciences (WVE) stock plunges as the company interim data from an early-stage trial for WVE-007, its RNA-based obesity medicine. Read more here.
Wave Life Sciences shares plunged >50% after Phase 1 INLIGHT data for WVE-007 showed <1% placebo-adjusted weight loss at six months. Find out why WVE is a Hold.
Anavex shares crash as the EMA indicates it won’t issue a positive opinion on its candidate Alzheimer’s drug. Here’s why long-term investors may still consider loading up on AVXL stock today.
Wave Life Sciences Ltd. (NASDAQ:WVE) shares fell 30% Thursday following the company’s announcement of interim Phase 1 data from its INLIGHT trial evaluating WVE ...
Loomis Sayles, an investment management company, released its fourth-quarter 2025 investor letter for “Small Cap Growth Fund” ...
Investor's Business Daily on MSN
Wave Life Sciences crashes 50% as 'body composition' fat-loss drug underwhelms
Wave Life Sciences stock crashed Thursday after the company's much-hyped "body composition" drug led to just 1% weight loss in six months.
W hile challenges persist in the short term, there are signs pointing toward long-term growth for life sciences, according to JLL’s 2024 Life Sciences Real Estate Perspective and Cluster Analysis. The ...
Read about the new Biocom Octane partnership. Discover how this collaboration expands capital and accelerator access for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results